EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Scemblix (asciminib hydrochloride) for chronic myeloid leukemia (BCR-ABL positive) and granted orphan designation to th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Novartis Europharm Limited. Decision date: 17/11/2025. Orphan medicine